# Sanofi: Phase 2 study terminated, 335 enrolled (Asthma)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Sanofi |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study |
| NCT ID | NCT06033833 |
| Phase | Phase 2 |
| Status | terminated |
| Conditions | Asthma |
| Intervention types | drug |
| Target enrollment | 335 |
| Site countries | United States, Argentina, Brazil, Canada, Chile, Hungary, Italy, Japan, Mexico, Poland, South Africa, South Korea |
| Posted | 2023-09-13 |
| Planned start | 2023-09-05 |
| Event | Terminated |
| Event date | 2026-09-22 |
| Last update posted | 2026-10-02 |

## Why this score
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.
- Phase 2: multi-site, larger budget.
- 335 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06033833). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.